LISIA SULLINS: Open Payments
NPI 1609937499 · ST SIMONS ISLAND, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 35 payments from 15 companies in 2025. Trend: 2023 $665 · 2024 $810 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $155 |
| AstraZeneca Pharmaceuticals LP | 3 | $67 |
| Lilly USA, LLC | 3 | $61 |
| Novo Nordisk Inc | 4 | $61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Lundbeck LLC | 2 | $36 |
| Amgen Inc. | 2 | $32 |
| PFIZER INC. | 2 | $30 |
| Exact Sciences Corporation | 1 | $24 |
Products named: VRAYLAR, MOUNJARO, XIFAXAN, CAPLYTA, REXULTI, Wegovy, AIRSUPRA, OTEZLA.
Industry payments across GA — which companies pay providers there.
